โ ViewAdvancedIndustry Deep Dives โบ Company & Industry Analysis
Addex Therapeutics Faces Critical Pipeline Review Amid Half-Year Results
Clinical-stage biopharma Addex Therapeutics reports its 2026 half-year results today, with investors closely watching for updates on its allosteric modulator pipeline. CEO Tim Dyer is set to address the company's neurological disorder research during a live investor webcast.
2mยท๐ 0